Military Weight-Loss drug trial pulled before it began

NCT ID NCT06468748

Terminated Disease control Sponsor: United States Army Research Institute of Environmental Medicine Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study aimed to see if the weight-loss drug Wegovy (semaglutide) could help active-duty military personnel lose weight and improve body composition without harming physical performance. It planned to enroll 0 participants and was withdrawn before starting. No results are available.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: semaglutide (Wegovy)
What this could lead to: If this trial had succeeded, it could have pointed toward a weight-loss option for military personnel that preserves physical performance.
What could go wrong: The study was withdrawn with zero participants, so no results are available. Even if run, it was small and open-label, limiting reliability.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OBESITY

Contacts and locations

Show contact details

Locations

USARIEM

Natick, Massachusetts, 01760, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.